Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555 · clinicaltrials.gov ↗

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Forms of Multiple Sclerosis

Interventions

DRUG: Ocrelizumab
DRUG: Ofatumumab

Sponsor

Novartis Pharmaceuticals